The earnings call reflects a mix of positive developments, such as early trial enrollment completion and strong financial positioning, countered by delays in drug approval and increased expenses. The sentiment is balanced with notable achievements and challenges.

Company Guidance -

Q3 2025

During the first quarter of 2025, Cytokinetics provided detailed guidance on several key metrics across its business operations. The company's financial position remained strong, with approximately $1.1 billion in cash, cash equivalents, and investments as of the end of the quarter. Research and development expenses increased to $99.8 million from $81.6 million in 2024, reflecting advancements in clinical trials and personnel costs. General and administrative expenses rose to $57.4 million, driven by investments in commercial readiness. The net loss for the quarter was $161.4 million, or $1.36 per share. For the full year 2025, the company maintained its financial guidance, expecting GAAP operating expenses between $670 million and $710 million, with a stock-based compensation range of $110 million to $120 million. Excluding stock-based compensation, expenses are projected between $550 million and $600 million. These figures incorporate the impact of a PDUFA date extension for aficamten, which affects the timing of launch expenses and increases R&D costs due to accelerated enrollment in the ACACIA trial.

Strong Start to Fiscal Year 2025

Cytokinetics reported a robust beginning to the fiscal year with significant progress across their projects, setting a solid foundation for future growth.

ACACIA-HCM Enrollment Completed Early

The pivotal Phase III clinical trial of aficamten in non-obstructive hypertrophic cardiomyopathy (nHCM) completed enrollment six months ahead of schedule, enabling top-line results in the first half of 2026.

High Interest in Salesforce Recruitment

The company received several thousand applications for sales positions, with a high level of interest and many candidates possessing cardiology experience.

Financial Position

Cytokinetics ended the first quarter with approximately $1.1 billion in cash, cash equivalents, and investments, providing a strong financial base for future operations.

Partnership with Sanofi in China

The collaboration with Sanofi is progressing to support the NDA review of aficamten with the NMPA, indicating potential for growth in the Chinese market.

Cytokinetics (CYTK) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CYTK Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	-1.52 / -	-1.36	―	―	―
Aug 07, 2025	2025 (Q2)	-1.43 / -1.12	-1.31	14.50% (+0.19)	―
May 06, 2025	2025 (Q1)	-1.37 / -1.36	-1.33	-2.26% (-0.03)	―
Feb 27, 2025	2024 (Q4)	-1.19 / -1.26	-1.38	8.70% (+0.12)	―
Nov 06, 2024	2024 (Q3)	-1.24 / -1.36	-1.35	-0.74% (-0.01)	―
Aug 08, 2024	2024 (Q2)	-1.06 / -1.31	-1.34	2.24% (+0.03)	―
May 08, 2024	2024 (Q1)	-1.14 / -1.33	-1.38	3.62% (+0.05)	―
Feb 27, 2024	2023 (Q4)	-0.96 / -1.38	-1.45	4.83% (+0.07)	―
Nov 02, 2023	2023 (Q3)	-0.74 / -1.35	-1.52	11.18% (+0.17)	―
Aug 03, 2023	2023 (Q2)	-1.14 / -1.34	-0.23	-482.61% (-1.11)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CYTK Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$35.25	―	―
May 06, 2025	$33.97	$33.04	-2.74%
Feb 27, 2025	$47.45	$46.00	-3.06%
Nov 06, 2024	$55.50	$55.84	+0.61%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Cytokinetics (CYTK) report earnings?

Cytokinetics (CYTK) is schdueled to report earning on Oct 30, 2025, After Close (Confirmed).

What is Cytokinetics (CYTK) earnings time?

Cytokinetics (CYTK) earnings time is at Oct 30, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CYTK EPS forecast?

CYTK EPS forecast for the fiscal quarter 2025 (Q3) is -1.52.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing